Lilly Is Attentive To ADHD: Tomoxetine Into Phase III; 2001 NDA Planned
Tomoxetine for attention deficit hyperactivity disorder could be the next neuroscience entry from Lilly, building on the Prozac and Zyprexa franchises.
Tomoxetine for attention deficit hyperactivity disorder could be the next neuroscience entry from Lilly, building on the Prozac and Zyprexa franchises.